Moreover, the use of drugs that increase NO availability (e.g., ACE inhibitors) has been associated with favorable COVID-19 outcomes, whereas treatment with drugs inhibiting NO production/release (e.g., proton pump inhibitors) has been associated with worse COVID-19 prognosis [40,41,42,43]. Here, ACE is linked to COVID-19.